1L NSQ NSCLCSTK-012pembrolizumabcarboplatinpemetrexedDana Farber Cancer InstituteSTK-012-101
…usions These are initial Phase 1a/b results of STK-012 + SoC in 1L NSQ NSCLC. STK-012 was well tolerated in combination with SoC and demonst…
1articles mentioning diseases
4disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: 1L NSQ NSCLC ×
1L NSQ NSCLC
This disease is selected. Its supporting articles are shown below.